Daniela Osorio Rivera
Agencia Latina de Noticias Medicina y Salud Pública
Agreed with the Revised Impressions of Medicine and Public Health, the Associated Chair of the Department of Pharmaceutical Sciences of the University of Puerto Rico, Dra. Magaly Martínez Ferrer, indicates that one in five men has been diagnosed with prostate cancer.
“In this type of cancer, when the prostate is able to cure through radiotherapy. Without embarrassment in patients who have metastasis, adjuvant therapy (anti-androgen and chemotherapy) is a very common second option. On the other hand, adjuvant therapies for menopause only involve a temporary suspension of the progression of the illness ” explained the specialist.
La Dra. Martínez Ferrer states that the treatment with which the specialists live this condition is by means of the probable chronic diagnostic factor evaluating the recent progression of biochemistry, and tomaning and considering the stratification between patients with risk and major ries.
This classification is made with the end of ten, the risk against the concentration of the prostate antigen. The specialist aggregator who knows the level of prostate antigen is fundamental for patients with cancer risk and intermediate, and that these patients may not be treated for risk risk.
“This disease is very irregular and progresses with a high degree of speed. Patients can present an increase in the concentration of the prostate antigen, although currently there are multiple treatment options available. These therapies only prolong general surveillance and develop rapid resistance ”, details the También Catedrática Asociada de la Universidad de Puerto Rico.
Stratification is based on general aspects of prostate cancer: the first, its clinical features such as: Combination evaluation of the value of the analysis of the specific prostatic antigen prevalence in the treatment and clinical condition of the tumor.
Secondly, there are molecular properties or biomarkers, as indicated by the specialist. The doctor also explained that the biomarker in these patients includes the study of the alterations in the genetic expression as much as the genetic level as a prototype.
Chemotherapy, inflammation and recurrence of prostate cancer.
La Dra. Martínez Ferrer argues that chronic inflammation, following the chronicle, is a determining factor that predisposes individuals to various cancers. Epidemiological studies suggest that inflammatory diseases predispose individuals to a mayor risk cancer to generate a microbial environment that contributes to the multiplication, migration, and metastasis of cancer cells.
The cancer of the prostate is advanced and metastatic through a combination of factors such as the microbiome of the tumor, the mediators and the cells in the tumor.
Chemicals are a group of chemically-attracted protein regulators that locate leukocytes and position them, forming a fundamental paper in the orchestration of humanitarian and inflammatory responses. Its main function is to provoke the coordinated movement of the cells in the place of inflammation.
The current therapeutic options for patients with cancer include surgery or radiation. Although it can be curative for many patients, up to 35% of patients with prostatectomy develop a biochemical recurrence of prostate cancer.
The temporary detection of cancer that is likely to trigger a biochemical recurrence can lead to the proactive use of therapeutic options before a biochemical recurrence.
For more information you can specify the next link: https://medicinaysaludpublica.com/medicamentos-y-covid-19/